These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1054 related articles for article (PubMed ID: 19210674)

  • 1. Prostate-specific antigen kinetics in localized and advanced prostate cancer.
    Fitzpatrick JM; Banu E; Oudard S
    BJU Int; 2009 Mar; 103(5):578-87. PubMed ID: 19210674
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of PSA and percent free PSA for staging and prognosis prediction in clinically localized prostate cancer.
    Pannek J; Partin AW
    Semin Urol Oncol; 1998 Aug; 16(3):100-5. PubMed ID: 9741413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of serum markers for prostate cancer.
    Stenman UH; Abrahamsson PA; Aus G; Lilja H; Bangma C; Hamdy FC; Boccon-Gibod L; Ekman P
    Scand J Urol Nephrol Suppl; 2005 May; (216):64-81. PubMed ID: 16019759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of prostate cancer: the impact of the European Randomized Study of Screening for Prostate Cancer (ERSPC).
    Schröder FH
    Can J Urol; 2005 Feb; 12 Suppl 1():2-6; discussion 92-3. PubMed ID: 15780157
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Limitations in the use of serum prostate specific antigen levels to monitor patients after treatment for prostate cancer.
    Vicini FA; Vargas C; Abner A; Kestin L; Horwitz E; Martinez A
    J Urol; 2005 May; 173(5):1456-62. PubMed ID: 15821460
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate cancer and prostate-specific antigen (PSA) screening in Austria.
    Vutuc C; Schernhammer ES; Haidinger G; Waldhör T
    Wien Klin Wochenschr; 2005 Jul; 117(13-14):457-61. PubMed ID: 16091872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Screening for prostate cancer: updated experience from the Tyrol study.
    Horninger W; Berger A; Pelzer A; Klocker H; Oberaigner W; Schönitzer D; Severi G; Robertson C; Boyle P; Bartsch G
    Can J Urol; 2005 Feb; 12 Suppl 1():7-13; discussion 92-3. PubMed ID: 15780158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Adenocarcinoma of the prostate].
    Dvorácek J
    Cas Lek Cesk; 1998 Aug; 137(17):515-21. PubMed ID: 9787503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate-specific antigen levels as a predictor of lethal prostate cancer.
    Fall K; Garmo H; Andrén O; Bill-Axelson A; Adolfsson J; Adami HO; Johansson JE; Holmberg L;
    J Natl Cancer Inst; 2007 Apr; 99(7):526-32. PubMed ID: 17405997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of subclinical cancers by prostate-specific antigen screening in asymptomatic men from high-risk prostate cancer families.
    Matikainen MP; Schleutker J; Mörsky P; Kallioniemi OP; Tammela TL
    Clin Cancer Res; 1999 Jun; 5(6):1275-9. PubMed ID: 10389909
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prostate-specific antigen].
    Eide IA; Angelsen A
    Tidsskr Nor Laegeforen; 2000 Sep; 120(21):2528-31. PubMed ID: 11070990
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Prostate cancer screening using prostate-specific antigen (PSA) determinations in plasma. National Academy of Medicine].
    Bourel M; Ardaillou R;
    Bull Acad Natl Med; 2003; 187(5):985-95. PubMed ID: 14979060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is prostate-specific antigen still the best tumor marker for prostate cancer?
    Leewansangtong S; Soontrapa S; Tantiwong A
    J Med Assoc Thai; 1999 Oct; 82(10):1034-40. PubMed ID: 10561969
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Using prostate-specific antigen screening and nomograms to assess risk and predict outcomes in the management of prostate cancer.
    Hammerer PG; Kattan MW; Mottet N; Prayer-Galetti T
    BJU Int; 2006 Jul; 98(1):11-9. PubMed ID: 16566811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor-associated forms of prostate specific antigen improve the discrimination of prostate cancer from benign disease.
    Mikolajczyk SD; Rittenhouse HG
    Rinsho Byori; 2004 Mar; 52(3):223-30. PubMed ID: 15137320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of prostate-specific antigen in the chemoprevention of prostate cancer.
    Crawford ED; DeAntoni EP; Ross CA
    J Cell Biochem Suppl; 1996; 25():149-55. PubMed ID: 9027612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate-specific antigen in clinical practice.
    Loeb S; Catalona WJ
    Cancer Lett; 2007 Apr; 249(1):30-9. PubMed ID: 17258389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PSA and other tissue kallikreins for prostate cancer detection.
    Stephan C; Jung K; Lein M; Diamandis EP
    Eur J Cancer; 2007 Sep; 43(13):1918-26. PubMed ID: 17689069
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Tumor markers in prostate cancer--clinical significance and future prospect of prostate specific antigen (PSA)].
    Tsuchiya N; Ohyama C; Habuchi T
    Gan To Kagaku Ryoho; 2005 Feb; 32(2):275-80. PubMed ID: 15751649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Baseline prostate-specific antigen level and risk of prostate cancer and prostate-specific mortality: diagnosis is dependent on the intensity of investigation.
    Connolly D; Black A; Gavin A; Keane PF; Murray LJ
    Cancer Epidemiol Biomarkers Prev; 2008 Feb; 17(2):271-8. PubMed ID: 18250343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 53.